

The 31st Annual General Meeting of Shareholders

Presentation on Business Report

March 2022





2022 Investment Strategy



Portfolio



Strategy & Tool




Professional Capabilities





Mgmt. System













Harvest, Allocation



Profit Realization and Return



Reorganize organizational and financial structures



Streamline Assets



'Market' ensures Proven Value









- Realize investment gains
- Streamline Asset
- Expand global market



'Exemplary Corporation'



ESG

Executing tasks and generating profits for investment



Securing

Mgmt. Transparency /Fairness

Periodic Communication



Agile response to change







Governance Story & Policy Direction on Shareholder Return

Finance Division




Aiming to enhance shareholder value and social value while achieving sustainable growth as investment specialist





Declared the 2021 Governance Story and established a foundation for evaluation and support from the market and stakeholders



Strengthened the momentum to implement ESG management principles by defining SK's unique Governance Story

- Overhauled the corporate structure charter
- Newly established HR Committee and ESG Committee to reinforce independence and professionalism
- Appointed a member in charge to facilitate communication with shareholders and stakeholders

Took initiative to strengthen SK Group's governance under BOD-centered responsible management



Secured objective evaluation/support from the market and stakeholders



To enhance connectivity between management activities and shareholder value by advancing the BOD-centered management in the future







To specify the procedure for the board of directors to evaluate the CEO

To achieve Governance Risk Zero for all SK members, including the company

To establish objective evaluationstandards for the company's
business activities in the market


"

To maximize shareholder value


by aligning the interests of governance, management, and general shareholders

Expanded DPS by leveraging ≥ 30% ordinary dividend from subsidiaries and some investment gains as dividend sources

Shareholder Return Policy (Present)



Dividend History



^{*} Interim dividends have been paid since 2018

^{**} KRW 0.9 tr of treasury stock was purchased in 2019



Utilize share buyback as a means to strengthen shareholder return, also to achieve the company value target for 2025 and to share investment gains with shareholders



Achieve company value target for 2025



As an investment company,

Share investment gains

with shareholders

Ordinary Dividend



Annual share buyback of 1% or more (up to 2025)

≥ 30% ordinary dividend income allotted

Allot investment gains from IPOs, etc

Maximize Total Shareholder Return

2021 Business Achievements & 2022 Strategic Direction Advanced Materials Investment Center



IDENTITY of Adv. Materials Investment Center



Investment expert specializing in innovative technology

Connect people-technology-customers based on insight into future technology and synergy within the group

Core Investment Areas







Specialty Gas

Copper Foil

SiC Wafer

Industrial Gas

SiC anode material

SiC Chip Design

Photo Resist

Single-crystal anode material

Ultra-fast EV Charger

- •
- •
- •









Solid Energy

- Next-generation Li Metal battery producer (SK secured 11.4% stake)
- Additional investment in April '21 / NYSE listing in Feb 2022



YPTX

 SiC power semiconductor design/mass production company
 Invested 33.6% stake of Yes Powertechnix



Signet EV

 Acquired Signet EV, North America's No. 1 ultra-fast EV fast charger manufacturer (Secured 51% stake)



Merger with SK Materials

- Integrated the investment and engineering capabilities of both companies
- Accelerated portfolios of new products

Strengthening Generic Competitiveness

- ▶ Improving product supply and demand as strong upstream demand
- ▶ Promoting expansion of new 300 mm Si Wafer plant based on customer LTA

Optimizing Portfolio

- ► Maximizing synergies between the existing business portfolios
- Building an Asset-Light business structure to maximize value of SK Inc.



Reinforcing Global Top Technological Competitiveness

- Equity investment in companies with global core technologies / Enhancing cooperation with joint ventures
 - To complete JV plant to produce G14 next-gen Si-C anode materials
 - To establish JV to produce single-crystal cathode materials in collaboration with Beijing Easpring

Nurturing New Future Businesses

- Commercializing new products with high difficulty (EUV photo materials, etc.)
- SiC Wafer: Preemptive promotion of capacity expansion (500K/yr, ~'25)

2021 Business Achievements & 2022 Strategic Direction

Green Investment Center



Establishing an investment story in decarbonization area and deriving 4 focus areas

Pre-Green Domain | Root Cause Resolution



New Energy | Alternative Energy

Hydrogen. Fuel cell Energy Solution Renewable Energy



Sustainable Food | Sustainable Food

Alternative Protein

Vertical Farming

Post-Green Domain | Resolution of existing issues



Clean Solution | Env./Tech.

Pollution·Waste Treatment

Waste-to-X

Re·upcycling



Carbon Mgmt. I CO₂ Treatment

Capture

Transport

Storage

Utilization



Securing a base for foothold investment/commercialization of globally promising assets within the decarbonization domain

New Energy | Alternative Energy

Invested in companies with promising technologies in the New Energy domain and secured the right to negotiate regarding domestic/Asian business



- Equity investment in an American hydrogen fuel cell development/production company
- Secured the position of the largest shareholder



- Invested in U.S. Turquoise hydrogen/carbonless solid carbon producer
- Secured exclusive rights of negotiation in Korea/China/Vietnam



- Equity investment in an American hydrogen fuel cell development/production company
- Secured exclusive rights of negotiation in Korea

Sustainable Food | Sustainable Food

Invested in leading companies by product in the sustainable food domain and secured the right to negotiate regarding domestic/Asian business



- Made an additional investment in the #1 fermentation-based alternative milk protein producer in the US
- Secured exclusive rights of negotiation in Korea and Vietnam



- Invested in a leading EU-based plant-based meat producer
- Secured exclusive rights of negotiation in Asia (13 countries)



• Invested in U.S. microbe-based alternative protein producers



- Co-investment to secure a portfolio of alternative foods in the Chinese market
- SK, Joyvio, Chinese PE/VC and local government involved

To secure the foundation for global anchor business and expedite domestic/Asia business and based on existing investment assets

Promoting the commercialization of investment assets

- ▶ Monolith: To launch Turquoise hydrogen/carbonless solid carbon-related domestic biz in earnest via JVA
- ► Fulcrum Bioenergy: To gain IPO value after domestic commercialization and additional equity inv.
- Perfect Day: To establish a foundation in the Asian market through JVs in Korea, China, Vietnam, and Asia
- Meatless Farm: To verify potential and promote Asian JV establishment as Anchor Biz

Acquiring Anchor Assets/BM in the CCUS area

To identify and secure anchor assets/BMs in the Global CCUS value-chain



Preoccupied the asset of future carbon-free energy sources

- To generate revenue by investing in promising technologies and companies in the renewable energy, hydrogen, and biofuel
- To enhance the value of SK Inc.'s stake by supporting member companies to achieve carbon neutrality/RE100 and expanding related industries

Revisiting ways to gradually liquidate existing assets related to fossil fuels.

➤ To review/execute measures to increase equity value by adjusting the existing fossil fuel-based portfolios

2021 Business Achievements & 2022 Strategic Direction

Bio Investment Center



SK Pharmteco recorded about 19% YoY growth in sales in 2021 and successfully expanded its business into the high-growth Cell & Gene Therapy CMO, obtaining additional future growth engines




SK Pharmteco recorded 19% YoY growth in sales in 2021


(based on 2021 total earnings)



Acquired French company Yposkesi in March 2021 Invested in US company CBM in December

* CBM (The Center for Breakthrough Medicines)







To advance into a global top-tier CMO by pursuing stable and high growth of the existing core business, synthetic drug business, and adding value to the new business, Cell & Gene Therapy, at an early stage

Synthetic drugs





Synthetic drug pipelines and longterm contracts are continuously increasing



To make additional investments in the Cell & Gene Therapy by attracting investment for growth funds




To increase the capacity of each US/European/Korean site to a proper level to handle rising volumes in a stable manner



Driving the expansion of commercial facilities of Yposkesi and CBM targeting mass production in 2023



To develop the second SK Biopharm to deliver miracles to patients and their families around the world by advancing into high-growth biopharmaceuticals beyond synthetic drugs



ADC: Antibody Drug Conjugate

YOU THANK YOU

